Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
The purpose of this trial is to look at how much a new trial drug get into body, such as when the drug concentration in your body reaches peak and how high the peak value is.
- Trial name
- NCT02468284
- Testing
- degarelix
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Previous study findings suggest that the efficacy limitations of the neoadjuvant treatment regimen combining docetaxel with androgen deprivation therapy are associated with protein synthesis.
- Trial name
- NCT07516704
- Testing
- Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy
- Volunteers
- 94 people
- Sponsor
- Zhongda Hospital
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03070886
- Testing
- Bicalutamide, Degarelix, Docetaxel
- Where
- 313 sites in United States, Canada and 1 more
- Volunteers
- 612 people
- Sponsor
- NRG Oncology
Risk of Bone Fracture Occurrences
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
- Trial name
- TREAT2 (NCT01214291)
- Testing
- Toremifene
- Where
- United States
- Sponsor
- GTx
Prostate Cancer, Insulin Resistance
Insulin Resistance and Androgen Deprivation Therapy
Prostate cancer is the most common malignancy amongst men in United States. Androgen deprivation therapy (ADT) with long acting gonadotropin releasing hormone agonists is routinely used as adjuvant therapy in intermediate and…
- Trial name
- NCT04995978
- Testing
- Pioglitazone 30 mg
- Where
- United States
- Sponsor
- St. Louis University
Prostatic Neoplasms
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive…
- Trial name
- NCT03007732
- Testing
- Pembrolizumab, SD-101, Leuprolide acetate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- David Oh
Prostate Cancer, Metabolic Syndrome
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
This is a multi-centre, double-blind, randomized phase III trial comparing metformin to placebo in patients with advanced prostate cancer starting (or have recently started) androgen deprivation therapy (ADT).
- Trial name
- PRIME (NCT03031821)
- Testing
- Metformin
- Where
- 16 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Urologic Oncology Group
Prostate Neoplasms
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have…
- Trial name
- NCT01715285
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 208 sites in Argentina, Australia and 31 more
- Volunteers
- 1,209 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Oligo-metastatic prostate cancer (OMPCa) is considered as an intermediated state between localized and poly-metastatic disease. Various retrospective studies and prospective clinical trials are carrying out to validate whether…
- Trial name
- NCT05212857
- Testing
- Leuprolide acetate, Goserelin acetate, Triptorelin acetate
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Prostate Cancer
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
RATIONALE: Specialized radiation therapy that delivers a high-dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00528866
- Testing
- bicalutamide, docetaxel, flutamide
- Where
- 70 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery.
- Trial name
- NCT01946165
- Testing
- Abiraterone Acetate, Prednisone, Enzalutamide
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side…
- Trial name
- NCT06218667
- Testing
- Copanlisib, Degarelix, Radical Prostatectomy
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
Background: Pox viral vectors can induce a PSA-specific T-cell responses and clinical responses in patients with advanced prostate cancer.
- Trial name
- NCT00096551
- Testing
- Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional…
- Trial name
- NCT05169112
- Testing
- Lupron Depot
- Where
- 3 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer.
- Trial name
- NCT02059213
- Testing
- Ibrance, Bicalutamide, Zoladex
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects…
- Trial name
- NCT07335796
- Testing
- BMS-986165, Degarelix
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Prostate Cancer (PCa) in ADT, Rehabilitation
Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
This is a drug-free, single arm, single center, superiority, interventional study aimed at treatment feasibility. The main aim of the current study is to assess feasibility of a tailored exercise program as measured by adherence…
- Trial name
- ReCaP (NCT06238596)
- Testing
- rehabilitation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Cancer
Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer.
- Trial name
- NCT03938766
- Testing
- PSMA PET/CT
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jewish General Hospital
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
Osteoporosis, Prostate Cancer
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
RATIONALE: Preventing bone loss in patients who are undergoing androgen ablation for prostate cancer may decrease the risk of fractures and may help patients live more comfortably.
- Trial name
- NCT00043069
- Testing
- calcium carbonate, cholecalciferol, Estrogen Antagonists
- Where
- 114 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- Alliance for Clinical Trials in Oncology